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Introduction
The clinical hallmark of Fanconi anemia (FA) is the develop-
ment of pancytopenia (loss of blood cells) in childhood (Schmid 
and Fanconi 1978; Butturini et al., 1994; Alter 1995). There is a 
progressive loss of hematopoietic stem cells by enhanced apop-
tosis, and it affects all blood lineages (for review see Grompe 
and D’Andrea 2001). Another consistent feature of FA is a high 
propensity toward both hematological and nonhematological 
malignancies, including myelodysplastic syndrome, acute my-
elogenous leukemia, and squamous cell carcinomas. A wide va-
riety of birth defects, such as short stature, skeletal abnormalities, 
abnormal skin pigmentation, and developmental abnormalities 
of other organs, are also observed. Markedly reduced life ex-
pectancy has been observed in FA patients with death resulting 
from hematological complications and cancer. Thus, under-
standing the basis of the bone marrow failure is of critical im-
portance to improve current treatment approaches for patients 
with FA.
The cellular phenotype of FA is characterized by the 
  occurrence of spontaneous chromosomal aberrations and hyper-
sensitivity to DNA cross-linking agents, such as mitomycin C 
(MMC) and diepoxybutane. There are 12 complementation 
groups (A–C, D1, D2, E–G, I, J, L, and M), and 11 of the FA 
genes have been cloned (D’Andrea 2003; Meetei et al., 2004; 
Thompson 2005). A key event in the FA pathway is the activa-
tion of FA subtype D2 protein (FANCD2) by monoubiquitina-
tion, which critically depends on the formation of a core complex 
of at least eight FA proteins (FANCA–C, E–G, L, and M) in the 
nucleus, in which FANCL is likely to function as the E3 ubiqui-
tin ligase (Meetei et al., 2003, 2004; Thompson 2005).
Localization studies suggest that a high molecular weight 
FA complex is found in both the nucleus and cytoplasm 
  (Thomashevski et al., 2004; Mi and Kupfer, 2005). For example, a 
microscopic study revealed that FANCA and FANCG are cyto-
plasmic in G1 and G2-M phase but are predominantly nuclear 
during S phase (Mi and Kupfer, 2005). In addition, the FANCC 
protein has been found to interact with several cytoplasmic 
  proteins involved in redox metabolism, including GSTP1 and 
the molecular chaperones GRP94 and HSP70 (Hoshino et al., 
1998; Cumming et al., 2001; Otsuki et al., 2002; Pang et al., 
2002). FANCG interacts with CYP2E1, which is associated 
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ells from patients with Fanconi anemia (FA), an 
inherited disorder that includes bone marrow fail-
ure and cancer predisposition, have increased sen-
sitivity to oxidative stress through an unknown mechanism. 
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Cells from the FA-A and -C subtypes also have PRDX3 
cleavage and decreased peroxidase activity. This study 
demonstrates a role for the FA proteins in mitochondria 
witsh sensitivity to oxidative stress resulting from dimin-
ished peroxidase activity. These defects may lead to apop-
tosis and the accumulation of oxidative DNA damage in 
bone marrow precursors.
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with the production of reactive oxygen species (ROS) and the 
bioactivation of carcinogens, possibly implicating FANCG in 
protection against oxidative damage (Futaki et al., 2001, 2002). 
These data suggest that the FA proteins may function in more 
than one cellular compartment.
Oxygen sensitivity of FA cells was fi  rst reported by Joenje 
et al. (1981), and further studies demonstrated abnormal oxygen 
metabolism of FA cells, suggesting a defective antioxidant 
mechanism (Schindler and Hoehn 1988; Pagano 2000). In par-
ticular, oxidative damage and a senescent phenotype in response 
to hypoxia followed by reoxygenation is accentuated in FA cells 
(Zhang et al., 2005). In FA fi  broblasts, however, the activity 
of antioxidative enzymes, including catalase, superoxide dis-
mutase, glutathione reductase, and phospholipid hydroperoxide 
glutathione peroxidase, are normal (Gille et al., 1987;  Ruppitsch 
et al., 1997). Oxidative stress caused multimerization and an 
  increased interaction of FANC proteins (Park et al., 2004). 
  Antioxidants have been shown to be benefi   cial for DNA 
  stabil  ity and survival of FA cells (Porfi  rio et al., 1989; Ruppitsch 
et al., 1997). Thioredoxin (Trx) is an intracellular antioxidant 
and regulator of redox-sensitive gene expression. The overex-
pression of Trx in FA fi  broblasts prevents the cytotoxic and 
DNA-damaging effect of MMC and diepoxybutane (Ruppitsch 
et al., 1998), suggesting a direct association of oxidative stress 
with the primary genetic defect in FA (Pagano, 2000; Ahmad 
et al., 2002; for review see Pagano and Youssoufi  an 2003). This 
hypothesis is strengthened by the fi  nding that Fancc and super-
oxide dismutase double knockout mice exhibit severe defects in 
hematopoiesis, including histological evidence of bone marrow 
hypoplasia (Hadjur et al., 2001). These biochemical and genetic 
data strongly suggest that FA cells, including subtypes A, C, 
and G, experience increased oxidative stress, which can alter 
multiple cellular processes such as apoptosis, senescence, and 
DNA damage.
Although Blom et al. (2004) identifi  ed evolutionally con-
served tetratricopeptide repeat domains in the FANCG protein, 
little is known about the biochemical function of the FANCG 
protein. To determine potential functional roles of FANCG pro-
tein, we performed a yeast two-hybrid screen. Peroxiredoxin-3 
(PRDX3), the major Trx-dependent mitochondrial peroxidase, 
was identifi  ed as interacting with FANCG.
Mitochondrial PRDX3 is an important cellular antioxidant 
that regulates physiological levels of H2O2, leading to decreased 
cell growth while protecting cells from the apoptosis-inducing 
effects of high levels of H2O2 (Nonn et al., 2003). PRDX3 de-
pletion resulted in the acceleration of apoptosis, with increased 
rates of ∆Ψm (mitochondrial membrane potential) collapse, 
cytochrome  c release, and caspase activation (Chang et al., 
2004). PRDX3 contains a mitochondrial localization sequence, 
is found exclusively in the mitochondrion, comprises 5% of the 
total mitochondrial matrix, and uses mitochondrial Trx2 as the 
electron donor for its peroxidase activity (Watabe et al., 1997; 
Gourlay et al., 2003). PRDX3 expression is induced by oxidants 
in the cardiovascular system to maintain oxidant homeostasis 
(Araki et al., 1999; Wonsey et al., 2002). PRDX3 expression is 
regulated by myc (Wonsey et al., 2002), and elevated levels of 
PRDX3 protein were detected in breast cancers (Noh et al., 2001) 
and hepatocellular carcinoma (Choi et al., 2002). Prdx1- and 
Prdx2-defi  cient mice have severe hematological disorders and 
hemolytic anemia. Prdx1 knockout mice also develop malig-
nant cancers (Lee et al., 2003; Neumann et al., 2003).
In this study, we demonstrate that the FANCG protein in-
teracts physically with PRDX3 and that the proteins colocalize 
in the mitochondria. In FA cells from patients with subtypes G, 
C, and A, PRDX3 undergoes cleavage by a calpainlike cysteine 
protease, and mitochondrial peroxidase activity is diminished. 
These defects are associated with distorted mitochondrial struc-
tures. The overexpression of PRDX3 can restore the resistance 
of FA cells to H2O2 exposure, and down-regulation increases 
MMC sensitivity, suggesting that diminished mitochondrial 
peroxidase activity underlies the sensitivity of FA cells to 
 oxidative  stress.
Results
FANCG interacts with the mitochondrial 
protein PRDX3
To identify interacting partners of the FANCG protein, we ini-
tially used both the N-terminal (aa 1–322) and C-terminal (aa 
301–622) regions of the FANCG protein as baits for yeast two-
hybrid analysis. A human B lymphocyte cDNA library cloned into 
the pACT vector was used as prey for the two-hybrid screen. The 
bait and prey were sequentially transformed into yeast, and posi-
tive colonies were selected by growth on the minimal synthetic 
plates containing 3-aminotriazole lacking adenine, tryptophan, 
and leucine. These clones were further tested for β-galactosidase 
activities, and positive plasmids were isolated and sequenced. 
A cDNA encoding aa 1–256 of the PRDX3 protein was identi-
fi  ed in the screen using the C-terminal portion of FANCG as bait 
(Fig. 1, A and B). A bait construct containing a specifi  c missense 
mutation (G546R) identifi  ed in an FA-G patient was used to fur-
ther probe this interaction (Nakanishi et al., 2001). Quantitative 
β-galactosidase assays demonstrate that wild-type PRDX3 
interacts with the FANCG bait, and this activity is diminished 
when the mutant FANCG bait is used (Fig. 1 B).
To confi  rm the interaction of PRDX3 and FANCG in 
mammalian cells, we used a coimmunoprecipitation assay. The 
full-length wild-type and G546R mutant FANCG cDNAs were 
cloned into the pCDNA3 mammalian expression vector as a fu-
sion with the HA epitope. An unrelated HA-tagged nuclear fac-
tor 1 (NF1) construct, pCH-HA-NF1, was used as a negative 
control (Mukhopadhyay et al., 2001). These expression con-
structs were transfected individually into COS-1 cells. 48 h af-
ter transfection, total cell lysates were precipitated with rabbit 
C-terminal PRDX3 antibody. The mutant and wild-type FANCG 
constructs were expressed equivalently when probed with the 
HA antibody (Fig. 1 C, input). Immunoprecipitated proteins 
were analyzed on SDS gel followed by immunoblotting with 
HA antibody (Fig. 1 C, top). The HA-FANCG protein is de-
tected consistently with the endogenous PRDX3 protein inter-
acting with the HA-FANCG protein. Similar to our two-hybrid 
result, there was little to no interaction between the endogenous 
PRDX3 protein and the HA-FANCG G546R mutant protein, 
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HA-NF1–tagged protein. This further demonstrates the speci-
fi  city of the interaction between FANCG and PRDX3.
A reverse experiment was performed with the same ly-
sates but with coimmunoprecipitation using the anti-HA epit-
ope antibody. The immunoprecipitated proteins were visualized 
by Western blotting performed with PRDX3 antibody (Fig. 1 C, 
bottom). This antibody detects endogenous PRDX3 protein in 
the immunoprecipitate from cells transfected with wild-type but 
not G546R mutant HA-FANCG or HA-NF1. Therefore, by 
two-hybrid analysis and coimmunoprecipitation assays, the 
FANCG and PRDX3 proteins interact. This interaction is di-
minished in FANCG protein containing the patient-associated 
G546R mutation.
FANCG protein is localized to mitochondria
Previous studies have found that PRDX3 is exclusively a mi-
tochondrial protein (Wonsey et al., 2002; Nonn et al., 2003). 
Therefore, we wanted to identify whether FANCG protein co-
localized with PRDX3 within the mitochondria. The pDsRed2-
Mito plasmid was used to identify mitochondria. We transfected 
the pCDNA3-HA FANCG and pDsRed2-Mito constructs into 
HeLa cells and used immunofl  uorescence to detect the locali-
zation of transfected proteins. C-terminal PRDX3 antibody was 
used to detect the endogenous PRDX3 protein. Inspection of 
asynchronous HeLa cells transfected with the HA-FANCG con-
struct revealed cells with localization either in the nuclear or cy-
toplasmic compartments as previously reported (Mi and Kupfer 
2005). Fig. 2 shows a deconvolution analysis of a representative 
cell with predominantly cytoplasmic staining of HA-FANCG. 
Figure 1.  FANCG protein interacts with PRDX3. (A) Colonies of yeast 
strain PJ-69-4A transformed with the indicated bait and prey vectors were 
patched on selective synthetic medium plates lacking adenine, tryptophan, 
and leucine and grown for 2–3 d at 30°C. EV, empty vector. (B) β-
galactosidase activity assays were measured on protein lysates from expo-
nentially growing liquid yeast cultures containing the indicated plasmids. 
FANCG-G546R contains the FANCG cDNA with an introduced missense 
mutation in pAS1. Error bars represent the SEM of three independent de-
terminations. (C) Total protein lysates from COS cells that were transfected 
with empty vector (E), HA-FANCG (F), HA-FANCG-G546R (F
M), or HA-NF1 
(NFI) constructs were analyzed. In the top panel, lysates were immunopre-
cipitated with PRDX3 C-terminal antibody (IP:PRDX3). 10% of the protein 
lysates used in the immunoprecipitation was electrophoresed on the right 
side of the blot (input). The membrane was serially probed with anti-HA, 
PRDX3, and tubulin antibodies. In the bottom panel, the same lysates were 
immunoprecipitated with the anti-HA antibody (IP:HA) and 10% of the 
  lysate electrophoresed on the right (input). The blot was probed with the 
PRDX3 antibody.
Figure 2.  In vivo colocalization of FANCG and PRDX3 in mitochondria. 
(A–F) Fluorescent localization experiments were performed on HeLa cells 
transfected with the indicated plasmids, including pDsRed2-Mito (RFP-
tagged mitochondrial marker; A–C) and HA-FANCG (A–F). Anti-HA 
monoclonal antibody and FITC-labeled secondary antibody were used to 
detect HA-FANCG. C-terminal PRDX3 polyclonal antibody and Texas 
red–labeled secondary antibody were used to detect the endogenous 
PRDX3. RFP was observed with the same red ﬁ  lter as used for Texas red. 
(G) HeLa cells transfected with the HA-FANCG wild type (left) or HA-
FANCG G546R mutant (right) construct were fractionated into a nuclear 
fraction (N) and cytoplasmic fraction containing organelles (C/M). Mito-
chondria (M) were further puriﬁ  ed. Lysates were electrophoresed and hy-
bridized with anti-HA monoclonal antibody and the indicated polyclonal 
antibodies. Cytochrome c, tubulin, and lamin B represent mitochondrial, 
cytoplasmic, and nuclear markers, respectively. (H) Mitochondrial lysates 
were made from FA-G mutant (EUFA316) and corrected lymphoblasts and 
HeLa cells transiently transfected with HA-FANCG. The lysates were elec-
trophoresed, transferred, and hybridized with FANCG and cytochrome c 
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There was substantial colocalization of HA-FANCG with the 
mitochondrial marker (Fig. 2, A–C). As expected, PRDX3 co-
localized with the mitochondrial marker (not depicted; see Fig. 
4 A). Staining of both the HA-FANCG and endogenous PRDX3 
demonstrates colocalization (Fig. 2, D–F). These immunofl  uo-
rescent experiments suggest that both the FANCG and PRDX3 
proteins are found within mitochondria.
To confi  rm the localization of FANCG in the mitochon-
drial compartment, we performed immunoblotting of lysates 
from fractionated cells. After transfection with either the HA-
FANCG wild-type or G546R mutant construct, HeLa cells were 
fi  rst fractionated into a nuclear and cytoplasmic lysate. The 
cytoplasmic lysate contains organelles, including mitochondria. 
Mitochondria were then further isolated from this extract. 
  Immunoblots of the fractionated lysates from cells transfected 
with the wild-type construct are shown in the left panel in Fig. 
2 G. Immunoblotting with appropriate antibodies demonstrates 
the expected pattern with cytoplasmic/mitochondrial lysates 
containing both tubulin and cytochrome c and the purifi  ed 
mitochondrial lysate containing only cytochrome c. Consistent 
with our immunofl  uorescence experiments, antibody to the HA 
epitope detects a single protein band with the expected size of 
HA-FANCG in both the mitochondrial and nuclear lysates. The 
pattern of localization of the G546R mutant protein is similar 
to the wild-type HA-FANCG (Fig. 2 G, right). Thus, the lack 
of coimmunoprecipitation of PRDX3 and mutant FANCG is not 
related to mislocalization of the mutant protein and is most 
likely caused by a direct impact of the mutation on FANCG–
PRDX3 interaction.
Because transiently transfected proteins may be localized 
differently in comparison with the endogenous protein, we also 
isolated mitochondrial extracts from the FA-G mutant and sta-
bly corrected lymphoblasts and also from HeLa cells transiently 
transfected with HA-FANCG as a control (Fig. 2 H). An anti-
body to a FANCG peptide detects the FANCG band in the mito-
chondrial lysate of HeLa cells and FA-G–corrected cells but not 
in the FA-G mutant cells (Fig. 2 H). Thus, both the immunofl  uo-
rescent and Western blot assays are consistent with a portion of 
FANCG protein localizing to the mitochondria.
A low molecular weight form of PRDX3 
protein (PRDX3-S) is found in FA-G mutant 
lymphoblasts and in FANCG-corrected 
cells under oxidative stress
To understand the physiological relevance of the interaction be-
tween FANCG and PRDX3 in mitochondria, we determined the 
expression of PRDX3 in a FA-G mutant lymphoblast cell line 
compared with FA-G–corrected cells. We isolated total protein 
from both the mutant and corrected FA-G lymphoblasts, and 
equal amounts of protein were analyzed by Western blotting 
with C-terminal PRDX3 antibody (Fig. 3 A). In addition to the 
expected 25-kD protein, we found an additional smaller molecular 
Figure 3.  Proteolytic cleavage of PRDX3 by a cal-
painlike cysteine protease in the FA-G mutant lympho-
blasts and in FA-G–corrected cells after oxidative 
stress. (A) Total protein was isolated from FA-G mutant 
(EUFA316) and corrected lymphoblasts and immuno-
blotted with C-terminal PRDX3 antibody. The mem-
brane was stripped and probed with tubulin antibody 
(bottom). Protein size markers are indicated on the right. 
(B) Mitochondrial proteins were isolated from corrected 
and mutant FA-G lymphoblasts (EUFA316) and hybrid-
ized with C-terminal PRDX3 antibody. Cells were 
treated with the indicated amounts of H2O2 for 90 min. 
The ﬁ  lter was stripped and probed with cytochrome c 
antibody (bottom). M represents the lane with protein 
size markers. (C) FA-G (mutant) lymphoblasts were 
treated without (lane 1) and with (lane 2) ALLN (cysteine 
protease inhibitor) for 4–5 h. Mitochondrial proteins 
were then isolated, and Western blotting was per-
formed with the C-terminal PRDX3 antibody. The same 
membrane was stripped and probed with cytochrome 
c antibody (bottom). (D) A constant amount of in vitro–
transcribed/translated 
35S-labeled PRDX3 protein incu-
bated without (lane 1) and with recombinant calpain II 
in increasing amounts (0.25–1.5 μg; lanes 2–5) in the 
presence of calpain buffer, which contains 20 mM 
CaCl2. In lane 6, the same amount of PRDX3 was incu-
bated with 1.5 μg calpain II in the presence of 20 mM 
EGTA. (E) A constant amount of in vitro–transcribed/
translated 
35S-labeled PRDX3 incubated without (lane 1) 
and with recombinant calpain II (lane 2). 
35S-labeled 
PRDX3 incubated with mitochondrial extract from 
FA-G–corrected lymphoblasts (lane 3), FA-G mutant 
lymphoblasts (lane 4), and FA-G–corrected lympho-
blasts treated with 1 mm H2O2 for 90 min before lysis. 
(F) A constant amount of in vitro–transcribed/trans-
lated 
35S-labeled PRDX3 was incubated with 10 μl 
  calpain II (lanes 2–6) in the presence of in vitro–
  translated 
35S-labeled FANCG in increasing amounts 
(10, 20, 40, and 50 μl; lanes 3–6).PEROXIREDOXIN-3 IN FANCONI ANEMIA • MUKHOPADHYAY ET AL. 229
mass band (named PRDX3-S) of  16 kD in the lysates from 
FA-G mutant cells (Fig. 3 A, lanes 3 and 4). This band was not 
seen in the FANCG-corrected FA-G cells (Fig. 3 A, lanes 1 and 
2). To determine whether the PRDX3-S species is also a mito-
chondrial protein, we isolated the mitochondria from the mutant 
and corrected lymphoblasts. Similar to the whole cell lysates, 
PRDX3-S is found in the mitochondrial extracts of untreated 
FA-G mutant cells (Fig. 3 B, lane 4) but not the corrected cells 
(Fig. 3 B, lane 1). Previous investigators have reported that FA 
cells are sensitive to oxidative stress (for review see Pagano and 
Yousoufi  an, 2003). We treated the mutant and corrected FA-G 
cells with 100 μM and 1 mM of H2O2 for 90 min and isolated 
mitochondrial lysates for Western blotting. Interestingly, the 
FA-G–corrected cells exposed to 1 mM H2O2 demonstrate a 
band of the same mobility as the PRDX3-S band seen in unex-
posed FA-G mutant cells (Fig. 3 B, lanes 3 and 4). These results 
suggest that the PRDX3-S band may be generated by ongoing 
oxidative stress in the FA-G mutant lymphoblasts.
Calpainlike cysteine protease–mediated 
cleavage of PRDX3 in the FA-G 
lymphoblasts
Several proteases are activated by oxidative stress, including 
members of the cysteine protease family. To determine whether 
PRDX3-S is generated by the cleavage of full-length PRDX3 
with a cysteine protease, we added a cysteine protease inhibi-
tor, ALLN, to the medium 4–5 h before harvesting mitochon-
dria from the FA-G mutant lymphoblasts. Immunoblotting 
demonstrates that the ALLN treatment blocks generation of 
the PRDX3-S band (Fig. 3 C). This experiment suggests that a 
cysteine residue in PRDX3 is cleaved by a calpainlike cysteine 
protease active in the FA-G mutant cells. We tested this hypoth-
esis directly in vitro. We produced 
35S-labeled PRDX3 protein 
using a wheat germ in vitro transcription/translation assay and 
incubated the protein with recombinant calpain II enzyme. As 
demonstrated in Fig. 3 D, the addition of increasing amounts 
of calpain II (0.25–1.5 μg; lanes 2–5) to the in vitro–translated 
protein generates a band of the same molecular weight as 
PRDX3-S. Calpain II cleavage activity requires high calcium 
(20 mM), and the addition of 20 mM EGTA blocks the produc-
tion of PRDX3-S by 1.5 μg calpain II (Fig. 3 D, lane 6). These 
data are consistent with the endogenous PRDX3-S band seen in 
Western blots being a cleavage product of full-length PRDX3.
The fi  nding of PRDX3-S in Western blots of lysates from 
isolated mitochondria (Fig. 3 B) suggests that the protease 
  activity is mitochondrial in origin. To test this directly, we incu-
bated in vitro–translated 
35S-labeled PRDX3 protein with mito-
chondrial extracts isolated from untreated FA-G mutant and 
FA-G–corrected cells before and after exposure to 1 mM H2O2. 
The cleavage product PRDX3-S was generated by incubation 
with the untreated FA-G mutant mitochondrial extract, but only 
from FA-G–corrected cells after exposure to oxidative stress 
(Fig. 3 E). The addition of in vitro–translated FANCG protein 
protects PRDX3 from calpain-mediated cleavage (Fig. 3 F). 
  Collectively, these results suggest that PRDX3 is cleaved by a 
mitochondrial calpainlike cysteine protease in vivo to produce 
PRDX3-S. This protease activity is continuously active in FA-G 
mutant cells and can be induced in FA-G–corrected cells by 
acute exposure to H2O2.
Mislocalization of PRDX3 and distorted 
mitochondrial structure in FA-G ﬁ  broblasts
PRDX3 has been reported as an exclusively mitochondrial pro-
tein that reduces the level of H2O2 continuously generated in 
mitochondria (Araki et al., 1999; Wonsey et al., 2002; Nonn 
et al., 2003). To determine whether the localization of PRDX3 
is altered in cells from FA-G patients, we performed immuno-
fl  uorescence of PRDX3 in FA-G mutant (PD352-F1°) and 
  corrected (PD352-F2) primary fi  broblasts and normal human 
primary fi  broblasts. The endogenous PRDX3 was hybridized 
with C-terminal PRDX3 antibody and was detected by FITC-
labeled anti–rabbit IgG secondary antibody. Localization of the 
FITC-stained PRDX3 with pDsRed2-Mito was studied by de-
convolution microscopy. As expected from prior studies (Wonsey 
et al., 2002; Nonn et al., 2003), in normal human fi  broblasts, 
there is nearly 100% colocalization of the mitochondrial and 
PRDX3 signals (Fig. 4 A). In contrast, in FA-G mutant cells, 
most of the PRDX3 (FITC signal) does not colocalize with 
the pDsRed2-Mito RFP marker (Fig. 4 B). Interestingly, in the 
FA- G–corrected cells, there is an intermediate pattern, with the 
amount of colocalization (yellow signal) intermediate between 
the FA-G mutant and normal fi  broblasts (Fig. 4 C).
Figure 4.  Mislocalization of PRDX3 and distorted mitochondrial structures 
in FA-G mutant ﬁ  broblasts. (A–C) Normal primary human ﬁ  broblasts (A), 
FA-G mutant (B), and FA-G–corrected (C) primary ﬁ  broblasts (PD352) were 
transfected with mitochondrial marker (pDsRed-Mito). The C-terminal PRDX3 
antibody and FITC-labeled secondary antibody were used to detect the en-
dogenous PRDX3 protein. Merge of the green and red images. Arrows 
(B) indicate the PRDX3 (green signals) that does not colocalize with the red 
mitochondrial marker in FA-G ﬁ  broblasts. (D and E) Transmission EM of 
FA-G mutant primary ﬁ   broblasts. Mitochondria from FA-G ﬁ  broblasts 
  demonstrate frequent elongation and irregular shapes with acute and right 
angle branching (arrows). Some mitochondria have a z-shaped focal con-
striction of their diameters and bleblike extensions. (F) Transmission EM 
of FA-G–corrected primary ﬁ  broblasts with occasional mitochondria that 
have irregular outlines and branching pattern (top two arrowheads) and more 
normal structure (bottom arrowhead). Bars (D), 600 nm; (E and F) 400 nm.JCB • VOLUME 175 • NUMBER 2 • 2006  230
These immunolocalization experiments suggested that 
there might be a distortion of mitochondrial structures in FA-G 
cells, which is only partially restored when the FANCG cDNA 
is reintroduced (FA-G–corrected cells). To study mitochondrial 
structure further, we performed EM on the same cell lines used 
for the immunolocalization studies. As shown in Fig. 4 (D and E), 
the mitochondrial structures are quite abnormal in FA-G cells. 
The FA-G mutant cells possess mitochondria with markedly 
  irregular outlines and sizes. There was noticeable bran  ching, 
  irregular angulation, and elongated shapes, including mitochon-
dria with acute and right angle outlines, as well as some with a 
z shape (Fig. 4 E, arrowheads). There were also   areas with con-
striction of the mitochondria, with decreased   diameters and 
elongation of the mitochondria with bleblike   extensions. 
The crista and internal structures of the mitochondria from both 
FA-G mutant and corrected cells did not show alterations. 
  Mitochondria from the FA-G–corrected cells (Fig. 4 F, top 
  arrowheads) had occasional mitochondria with irregular out-
lines and less noticeable branching. The majority of the mito-
chondria from corrected cells had more typical mitochondrial 
morphology (Fig. 4 F, bottom arrowhead). Overall, the   total 
number of abnormally shaped mitochondria in FA-G   mutant 
 fi broblast cells (Fig. 4, D and E) is higher compared with the 
corrected cells (Fig. 4 F). These immunofl  uorescent and EM 
structural experiments suggest that there are defects in both 
PRDX3 localization and mitochondrial structure in cells from 
FA-G patients, implicating defective mitochondrial function in 
FA patients. The lack of complete rescue in the FA-G cells after 
correction with the FANCG cDNA may result from ineffi  cient 
turnover of the abnormal mitochondria already formed in FA-G 
mutant cells.
PRDX3-S is also found in lymphoblasts 
from patients with FA subtypes C and A
Several lines of evidence argue that the proteins encoded by 
the different FA genes function coordinately. This includes the 
  similar clinical phenotypes of patients from the different 
  subtypes as well as biochemical experiments demonstrating 
that many FA proteins form a complex required for FANCD2 
monoubiquitination. Therefore, we tested whether the expres-
sion of PRDX3 protein is altered in FA-C and -A mutants and in 
corrected lymphoblasts, as these represent the most common 
FA subtypes. Isolation of mitochondrial protein and immuno-
blotting with C-terminal anti-PRDX3 antibody is shown in Fig. 5 A. 
PRDX3-S was found in FA-A and -C mutant lymphoblasts 
(Fig. 5 A, lanes 2 and 4) but not in the corresponding corrected 
lymphoblasts (Fig. 5 A, lanes 1 and 2). This result suggests that 
the loss of any one of these three FA proteins results in the 
cleavage of PRDX3 in untreated cells.
The aforementioned result could be an indirect effect sec-
ondary to diminished FANCG protein in these other subtypes 
or a direct effect of loss of the FANCA or FANCC function. 
Therefore, we determined endogenous FANCG expression in 
mitochondrial extracts of FA-A, -C, and -G mutant cells (Fig. 5 D). 
As expected, FANCG protein is absent from FA-G mutant cells. 
FANCG is present in the FA-C mitochondrial extract and is 
somewhat diminished in the FA-A extract.
Previous studies demonstrated diminished FANCG levels 
in FA-A cells (Waisfi  sz et al., 1999; Medhurst et al., 2006). The 
presence of FANCG protein in the mitochondria from FA-C 
cells suggests that PRDX3 cleavage is not simply caused by the 
loss of FANCG and that multiple FA proteins are required for 
the maintenance of PRDX3 integrity. This model is consistent 
with the fact that FA cells from multiple subtypes demonstrate 
increased sensitivity to oxidative stress (for review see Pagano 
and Youssoufi  an, 2003).
Mitochondrial peroxidase enzymatic 
activity is diminished in lymphoblasts 
from FA patient types G, C, and A
PRDX3 reduces the H2O2 level in mitochondria by catalyzing 
the conversion of H2O2 into H2O using Trx reductase (TR) and 
Figure 5.  PRDX3 cleavage product is present and peroxi-
dase activity is diminished in lymphoblasts from FA subgroups 
C, A, and G. (A) Mitochondrial proteins were isolated from 
FA-A (HSC72) and -C (HSC536) mutant and corrected lym-
phoblasts and hybridized with C-terminal PRDX3 antibody. 
The blot was stripped and reprobed with cytochrome c anti-
body. (B) Mitochondrial lysates from HeLa cells transiently 
transfected with HA-FANCG (lane 1), FA-G–corrected (lane 2), 
FA-A mutant (lane 3), FA-C mutant (lane 4), and FA-G   mutant 
(lane 5) lymphoblasts were probed with FANCG antibody. 
The membrane was stripped and reprobed with cytochrome c 
antibody. (C and D) Peroxidase activity of mitochondrial ex-
tracts isolated from FA mutant and corrected cells. Recombi-
nant PRDX1 and a buffer sample alone were used as controls. 
All samples contained equal amounts of TR, Trx, NADPH, and 
H2O2. Each bar represents the mean initial activity of the mito-
chondrial extract isolated from three different aliquots of the 
same cell line. Error bars represent the SEM.PEROXIREDOXIN-3 IN FANCONI ANEMIA • MUKHOPADHYAY ET AL. 231
Trx as electron donors (Kang et al., 1998). An important ques-
tion is whether the cleavage and mislocalization of PRDX3 
observed in the previous experiments is associated with al-
teration in mitochondrial peroxidase activity. We performed 
Trx-dependent peroxidase activity assays in mitochondrial 
lysates from mutant and corrected FA cells. We used recom-
binant PRDX1 as a positive control for these assays. In Fig. 
5 B, the addition of 0.6 μg of recombinant PRDX1 shows a 
ninefold higher peroxidase activity than the negative control, 
which contains all of the reagents except the enzyme. 0.6 μg 
mitochondrial lysate from the FA-G–corrected cells supplies a 
similar level of peroxidase activity. The mitochondrial extract 
from FA-G mutant cells showed almost a sevenfold lower per-
oxidase activity than the FA-G–corrected cells. We excluded 
the possibility of an inhibitor of peroxidase activity in the 
  mutant cells by assaying a 1:1 mixture of lysates from FA-G 
mutant and corrected cells. This activity was comparable with 
the FA-G–corrected lysates alone.
Similar to the fi  nding of the PRDX3-S cleavage product in 
FA-A and -C cells, mitochondrial extracts from FA-A and -C 
mutant (but not corrected) lymphoblasts also had decreased mito-
chondrial peroxidase activity similar to the FA-G mutant cells 
(Fig. 5 C). Given that PRDX3 is the major Trx-dependent 
mitochondrial peroxidase, these data suggest that the PRDX3-
mediated peroxidase activity is diminished in all three FA subtype 
mutant cells compared with corrected cells. Thus, we see both the 
cleavage of PRDX3 and diminished mitochondrial peroxidase 
activity in multiple FA subtypes.
Overexpression of PRDX3 suppresses 
the sensitivity of FA-G cells to H2O2
Our data are consistent with the decreased mitochondrial per-
oxidase activity of PRDX3 in cells from FA-G, -A, and -C pa-
tients as the basis of increased sensitivity to ROS. To test this 
hypothesis, we determined whether the transient overexpres-
sion of PRDX3 in FA-G mutant cells increases resistance to 
treatment with H2O2. FA-G mutant and corrected fi  broblasts 
(PD352-F1° and PD352-F2) were transfected with either the 
pEF6/His6 empty vector or PRDX3 expression construct pEF6-
PRDX3 using a protocol that transfects  80% of the cells. 48 h 
after transfection, cells were exposed to varying concentrations 
of H2O2 for 90 min, and the number of viable cells was de-
termined using the 3-(4,5-dimethyl-thiazol-2yl)-2,5-diphenyl-
tetrazolium bromide (MTT) colorimetric assay. As previously 
reported (Park et al., 2004), FA-G mutant cells have increased 
sensitivity to H2O2 compared with FA-G–corrected cells (Fig. 6). 
Transient transfection of PRDX3 restores the survival of FA-G 
mutant cells to similar levels as the FA-G–corrected cells trans-
fected with the empty vector.
Increase in MMC sensitivity 
but maintenance of FANCD2 
monoubiquitination in cells 
with diminished PRDX3 expression
We next determined whether decreasing PRDX3 expression in 
cells with a normal FA pathway would alter the response to 
MMC. HeLa cells were transfected with either a control siRNA 
or PRDX3 siRNA (as previously developed by Chang et al., 
2004) to reduce PRDX3 expression. Cells with diminished 
PRDX3 expression showed dose-dependent increases in cell 
death after 24 h of MMC treatment (Fig. 6 B), which is consis-
tent with a previous study of the impact of Trx levels on MMC 
sensitivity (Ruppitsch et al., 1998). The increase in MMC 
  sensitivity occurred despite the maintenance of FANCD2 
monoubiquitination in the PRDX3 knockdown cells (Fig. 6 C).
Discussion
Localization of FANCG in the mitochondria
FANC proteins, including G, A, and C, have been reported to be 
present both in the nucleus and cytoplasm. However, the meth-
ods used in previous studies did not distinguish between cyto-
plasmic and mitochondrial proteins (Thomashevski et al., 2004; 
Figure 6.  PRDX3 expression impacts sensitivity to oxidative stress and 
MMC independent of FANCD2 monoubiquitination. (A) FA-G mutant 
(PD352-F1°) and corrected (PD352-F2) ﬁ  broblasts were transfected with 
the pEF6/His6 vector (empty vector [EV]) or pEF6-PRDX3 (PRDX3). 24 h 
later, cells were exposed to H2O2 for 90 min, and their viability was as-
sessed with an MTT assay. A representative experiment is shown with the 
line going through the mean and error bars showing the minimum and 
maximum value for each cell line. (B) HeLa cells were transfected with con-
trol siRNA (white bars) or PRDX3 siRNA (black bars). 24 h later, cells were 
exposed to MMC for an additional 24 h, and the number of viable cells 
was determined by MTT assay. (C) HeLa cells were transfected with control 
or PRDX3 siRNA and subsequently treated with 40 ng/ml MMC for 24 h. 
Protein lysates were made, electrophoresed, and immunoblotted with anti-
bodies to PRDX3, FAND2, and KU70. The long (L) and short (S) FANCD2 
species are noted.JCB • VOLUME 175 • NUMBER 2 • 2006  232
Mi and Kupfer 2005; Medhurst et al., 2006). In this study, 
we present data based on two-hybrid interaction, coimmuno-
precipitation, and immunolocalization that the FANCG protein 
binds and colocalizes with PRDX3 in mitochondria. The inter-
action of these two proteins is lost in the patient-associated 
G546R-FANCG mutant protein. We specifi  cally demonstrated 
that a portion of FANCG localizes with mitochondria in HeLa 
and FA-G–corrected cells. These results suggest that the 
FANCG protein can translocate into mitochondria and interact 
with PRDX3.
Proteolytic cleavage of PRDX3 
in the FA lymphoblasts
The fi   nding of FANCG interacting with PRDX3 is further 
strengthened by the characterization of defects in the structure 
and function of PRDX3 in FA cells from subtypes A, C, and G. 
PRDX3 is one of the major proteins that controls the level of 
ROS in the mitochondria (Nonn et al., 2003), and the level of 
ROS impacts proliferation and apoptosis. Therefore, we focused 
our experiments on determining whether cells from FA patients 
have intrinsic defects in regulation of the PRDX3 protein and 
enzymatic activity. We fi   nd a proteolytic cleavage product, 
PRDX3-S, in FA cells that is also seen in corrected cells ex-
posed to high levels of H2O2. Importantly, the PRDX3-S prod-
uct is found in three different FA subtypes (G, C, and A), 
suggesting that multiple FA proteins are required to maintain 
the integrity of PRDX3 in the mitochondria.
We propose that the cleavage of PRDX3 in FA mutant 
cells or normal cells exposed to oxidative stress is caused by a 
calpainlike cysteine protease based on inhibition by ALLN 
in vivo and by in vitro cleavage assays using mitochondrial ex-
tracts from FA cells and recombinant calpains. Calpains, a fam-
ily of Ca
2+-activated neutral cysteine proteases, are involved in 
cell death in a variety of models. For example, p35 (a neuron-
specifi  c activator) is cleaved by calpain into p25, which accu-
mulates in the brains of Alzheimer’s patients (Lee et al., 2000). 
Although there are some reports of mitochondrial calpains, they 
are not well characterized (Chen et al., 2002; Daniel et al., 
2003). Oxidative stress can release Ca
2+ from the mitochondrial 
Ca
2+ pool (Pariente et al., 2001), which may then activate mito-
chondrial calpains. Our results suggest that this activation 
  occurs constitutively in FA cells. Further research to characterize 
mitochondrial calpains and to understand their activation by 
  oxidative stress is needed.
Mitochondrial peroxidase activity 
is diminished in FA cells
PRDX3 mediates the level of ROS through its peroxidase activ-
ity. The endogenous level of mitochondrial peroxidase activity 
is substantially reduced in FA-G, -A, and -C mutant cells, sug-
gesting that a basic function of FA proteins is to maintain the 
integrity and biochemical activity of PRDX3. Consistent with 
this model, the transient overexpression of PRDX3 restores the 
resistance of FA-G cells to acute oxidative stress. The loss of 
peroxidase activity in mitochondria from FA cells may result in 
ongoing oxidative stress with an increase in ROS and ROS-
mediated DNA damage (Chang et al., 2004).
The mechanism by which the FA proteins impact the 
structure and function of PRDX3 is not clear. Based on our fi  nd-
ing that the FANCG protein can bind PRDX3 protein directly, 
can prevent PRDX3 cleavage in an in vitro assay, and is local-
ized to the mitochondria, FANCG may have a direct protective 
effect. This binding is lost in the G546R mutant protein even 
though the mutant protein is still present in mitochondria. Given 
the relative cellular abundance of PRDX3 compared with FA 
proteins, it is possible that the FA proteins play a more transient 
role in the folding of PRDX3 or its proper translocation into the 
inner mitochondrial membrane. Further research is required to 
discern this protective mechanism.
Collectively, our data suggest that FA proteins have impor-
tant roles outside the nucleus in maintaining the structure and 
 peroxidase  activity of the mitochondrial PRDX3 protein. This is 
similar to the fi  nding that the p53 protein translocates to both the 
  nucleus and mitochondria after DNA damage (Marchenko et al., 
2000; Zhao et al., 2005). Others have also suggested the impor-
tance of PRDX3 in modulating levels of ROS and apoptosis 
in non-FA cells (Nonn et al., 2003; Chang et al., 2004). We pro-
pose that the loss of PRDX3 activity results in a negative feed-
back loop (Fig. 7). With decreased peroxidase activity, ROS can 
build up within mitochondria, triggering apoptosis as well as 
further activating calpainlike proteases to further cleave PRDX3, 
which is consistent with the constitutive PRDX3 cleavage 
  activity demonstrated in mitochondrial extracts of FA-G cells. 
Apart from cleavage, ROS can also directly interfere with 
PRDX3 activity by overoxidation of the active site cysteine to 
cysteine sulfi  nic acid. This form of inactivation may be particu-
larly important for PRDX3 because the rate of regeneration of 
active PRDX3 by sulfi  nylation is slower than for PRDX1 and 
PRDX2 (Woo et al., 2003).
This model suggests that cells from FA patients would ac-
cumulate mitochondrial lesions from constitutive oxidative stress 
and may result in the distorted mitochondrial structures seen in 
EM experiments. In addition, ROS can leak out of the mitochon-
dria and may cause nuclear DNA damage and stimulate apoptosis 
or the senescent phenotype described in bone marrow precursors 
of Fancc
−/− mice (Zhang et al., 2005). The reduction in PRDX3 
expression in non-FA cells results in increased sensitivity to 
MMC with an intact FANCD2 monoubiquitination pathway. 
Figure 7.  Schematic model of the regulation of PRDX3 activity and the 
impact of decreased PRDX3 activity on oxidative stress–induced apoptosis 
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In FA cells, the increased ROS-mediated DNA damage would be 
coupled with impaired DNA repair processes and could also 
increase genomic instability and cancer susceptibility. This model 
is consistent with the recent fi  nding in Saccharomyces cerevisiae 
that the loss of PRDX function increases the mutator phenotype 
of strains defi  cient in DNA repair functions (Huang and Kolodner 
2005). Thus, minimizing the production of ROS, inhibiting 
  calpainlike protease activity, or using treatments that activate 
other ROS scavenger pathways may achieve improvements in the 
FA phenotype.
Materials and methods
Yeast two-hybrid screen
The N-terminal (aa 135–1,093) and C-terminal (aa 1,044–2,000) regions 
of FANCG cDNA were cloned into pAS2-1 bait vector (CLONTECH Labo-
ratories, Inc.). A human B lymphocyte cDNA library fused with the GAL4 
activation domain (gift from S. Elledge, Harvard University, Boston, MA) 
was screened. A total of 800,000 transformants was screened in the yeast 
strain PJ-69-4A (Gietz et al., 1997). Colonies capable of growth on mini-
mal synthetic plates containing 3-aminotriazole and lacking adenine, tryp-
tophan, and leucine were selected. The liquid β-galactosidase activity 
assay was performed (Rose et al., 1981) to quantify the interaction of 
  speciﬁ  c bait-prey combinations.
Plasmids
Full-length FANCG cDNA was subcloned into the HindIII and NotI sites of 
pcDNA3 to encode an N-terminal HA epitope-tagged FANCG protein. 
PRDX3 cDNA was cloned into the BamH1 and Xba1 sites of the pEF6/
His6 mammalian expression vector (Invitrogen). pCH-HA-NF1 has been 
previously described (Mukhopadhyay et al., 2001). The construct pD-
sRed2-Mito encoding RFP fused to the mitochondrial targeting sequence 
from subunit VII of human cytochrome c oxidase was purchased from 
BD Biosciences.
Cell culture
HeLa and COS-1 cells were grown in DME and 10% FBS (American Type 
Culture Collection). The mutant and corrected FA-A (HSC72) and -C 
(HSC536) lymphoblasts were obtained from G. Bagby (Oregon Health 
Sciences University, Portland, OR) and H. Joenje (VU University Medical 
Center, Amsterdam, Netherlands), EUFA316 (FA-G corrected and mutant) 
cells were obtained from A. D’Andrea (Dana Farber Cancer Institute, Bos-
ton, MA), and PD352 cells were obtained from the Fanconi Anemia Re-
search Fund. Normal human ﬁ  broblasts were obtained from the American 
Type Culture Collection (cell line GM08398). All FA cells were grown in 
RPMI and 15% FBS except that the PD352-F ﬁ  broblasts were grown in 
α-MEM and 15% FBS. All cells were grown in a 37°C incubator with 5% 
CO2. Transfections were performed with Effectene (QIAGEN) according to 
the manufacturer’s protocol.
Immunoblotting
Polyclonal rabbit antibodies to PRDX3 were generated against peptides 
from N-terminal (G  E  F  K  E  L  S  L  D  D  F  K  G  K  Y  ) and C-terminal (S  P  T  A  S  K  E  Y  F  E  K  Y  H  Q  ) 
regions of mouse PRDX3 (Zymed Laboratories). Rabbit polyclonal antibody 
against a FANCG peptide was obtained from S.-H. Lee (Indiana University 
School of Medicine, Indianapolis, IN; Park et al., 2004). Sources of com-
mercial monoclonal antibodies were as follows: anti-HA (HA.11) antibody 
(Covance), cytochrome c antibody (BD Biosciences), α-tubulin (Oncogene 
Research Products), and FANCD2 (Novus).
Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer 
(50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 
mM NaCl, 1 mM EGTA, 1 mM PMSF, 1 mM sodium orthovanadate, 10 
mM sodium ﬂ   uoride, and Complete Protease Inhibitor Cocktail tablet 
[1 tablet/10 ml of buffer; Roche]). Protein concentration was determined by 
detergent-compatible reagent (Bio-Rad Laboratories). Samples were boiled 
with sample buffer (125 mM Tris-HCl, pH 6.8, 86 mM 2-mercaptoethanol, 
4% SDS, 10% glycerol [vol/vol], and 0.2 mg/ml bromophenol blue) for 5 
min and were subjected to 10–13% SDS-PAGE. After electrophoresis, pro-
teins were transferred to polyvinylidene diﬂ  uoride. Immobilon-P membrane 
(Millipore) using a submerged transfer apparatus (Bio-Rad Laboratories) 
was ﬁ  lled with 25 mM Tris base, 200 mM glycine, and 20% methanol. 
  After blocking with 5% nonfat dried milk in TBS-T (200 mM Tris-HCl, pH 
7.5, 150 mM NaCl, and 0.1% Tween 20), the membrane was incubated 
with the primary antibody diluted in TBS-T with 5% milk (1:1,000 dilution 
for both the HA and PRDX3 antibody). Other antibodies were used accord-
ing to the manufacturer’s recommendations. Appropriate HRP-linked 
  secondary antibodies were used for detection by ECL (GE Healthcare).
Coimmunoprecipitation
Cells were lysed with RIPA buffer, and  500 μg of lysate was incubated 
with 4–5 μl of antibody (HA) for 30 min on ice. 20 μl of protein A plus/
protein G agarose beads (Oncogene Research Products) was added and 
incubated overnight at 4°C with constant shaking. Beads were washed 
with either PBS or RIPA three to four times and boiled with the sample buffer 
for 5 min followed by 10% SDS-PAGE and immunoblotting as described in 
the previous section.
Immunoﬂ  uorescent microscopy
Cells were plated onto poly-L-lysine–coated coverslips in 60-mm dishes and 
transfected the next day with the indicated constructs using Effectene. 48 h 
later, the cells were ﬁ  xed for 30 min at RT in a 4% PFA-buffered solution and 
permeabilized with 0.5% Triton X-100 for 10 min at RT. Staining with either 
the polyclonal PRDX3 C-terminal antibody and/or monoclonal HA antibody 
at a 1:300 dilution was performed for 1 h at RT in TBS-T containing 5% non-
fat dairy milk. The species-speciﬁ  c ﬂ  uorescein (FITC)- or Texas red–conjugated 
secondary antibodies (Abcam) at a 1:400 dilution were applied for 1 h at 
RT followed by counterstaining with DAPI and mounting together with Vecta-
shield mounting medium (Vector Laboratories) for 10–15 min at RT in the 
dark. The cells were analyzed on a microscope (Axiovert 200M; Carl Zeiss 
MicroImaging, Inc.) equipped with a digital CCD camera (C4742-95-
12ERG; Hamamatsu) and the Openlab 3.1.5 and Volocity 2.1d19 software 
packages (Improvision) using a plan-Apochromat 63× NA 1.40 oil objec-
tive (Carl Zeiss MicroImaging, Inc.).
EM studies for mitochondrial structure of the FA cells
Primary ﬁ  broblasts of FA-G mutant (PD352-F1°) and corrected (PD352-F2) 
cells at approximately passage 8 were harvested and washed three to four 
times with 1× PBS. The cell pellets were ﬁ  xed in 3% glutaraldehyde and 
underwent graded dehydration and inﬁ  ltration with plastic to create plastic 
tissue blocks. Semithin sections stained with toluidine blue were created to 
determine the suitability for ultrastructural examination. Thin sections were 
prepared, placed on copper grids, and stained with uranyl acetate and 
lead citrate. The section was then examined with transmission EM to assess 
the ultrastructure of the mitochondria using an electron microscope (model 
1210; JEOL).
Preparation of mitochondrial protein
Cells were harvested, washed once with ice-cold PBS, pH 7.4, resus-
pended, and incubated in a hypotonic buffer (10 mM Tris, 10 mM NaCl, 
3 mM MgCl2, 1 mM EDTA, and 1 mM EGTA) for 30 min on ice. Cells were 
lysed by 15 strokes with a tight-ﬁ  tting Dounce homogenizer, and nuclei 
and unbroken cells were pelleted by centrifugation for 15 min at 600 g 
and 4°C. The supernatant was centrifuged for 20 min at 12,000 g and 
4°C to pellet mitochondria. The pellet was resuspended in lysis buffer (100 
mM Tris-HCl, pH 7.4, and 0.1% Triton X-100 supplemented with protease 
and phosphatase inhibitors as described for RIPA buffer) and broken by 
soniﬁ   cation for 15 s. Membranes were removed by centrifugation at 
12,000 g for 15 min at 4°C (Nonn et al., 2003). Mitochondrial protein 
was quantiﬁ  ed using protein reagent (Bio-Rad Laboratories).
Peroxidase assay
NADPH, recombinant human PRDX1, human Trx, and TR from rat liver 
were purchased from Sigma-Aldrich. The initial rate of NADPH oxidation 
was monitored spectrophotometrically (Ultraspec2100 Pro; GE Health-
care) at A340. The 150-μl reaction mixture contained 50 mM Hepes-NaOH, 
pH 7.0, 250 μM NADPH, 46 nM TR, 2.2 μM Trx, and 0.6 μg of recombi-
nant human PRDX1 or mitochondrial extract of the indicated cells. The re-
action was initiated by the addition of 0.5 mM H2O2 (Kang et al., 1998).
In vitro translation and calpain digestion
35S-labeled PRDX3 protein was produced by in vitro transcription-translation 
using the TNT-coupled wheat germ extract lysate (Promega). 10 μl of labeled 
PRDX3 protein was incubated with increasing amounts (0.25–1.5 μg) of rat 
recombinant calpain II (Calbiochem) or mitochondrial lysates and the acti-
vation buffer (20 mM CaCl2) for 10–15 min at 37°C. Calpain was diluted 
with assay buffer (50 mM Tris-HCl, pH 8.0). After digestion, the proteins JCB • VOLUME 175 • NUMBER 2 • 2006  234
were separated on a 10% SDS polyacrylamide gel and transferred to 
polyvinylidene diﬂ  uoride membrane to decrease background. The membranes 
were exposed to phosphorimager screen (Molecular   Dynamics) for quanti-
tative analysis as well as x-ray ﬁ  lm (Kodak).
H2O2 sensitivity assay
Approximately 10
4 FA-G primary ﬁ  broblasts (mutant, PD352F1°, and cor-
rected PD352-F2) were split into 96-well plates. 24 h later, cells were 
transfected with the indicated construct using Effectene. 48 h after transfec-
tion, cells were treated with H202 for 90 min. Cells were washed several 
times with PBS, and 15 μl MTT (5 mg/ml in PBS) was added to each well 
(Denizot and Lang 1986). Plates were incubated for 4 h, 150 μl DMSO 
was added to each well, and the optical density at 550 nm was deter-
mined with a plate reader. Varying numbers of each cell line were plated, 
and, 24 h later, the MTT assay was performed. These data were used for 
log-linear regression of cell number versus OD550 to determine the number 
of viable cells remaining after treatment with H2O2.
MMC sensitivity assay
The PRDX3 and control siRNAs (as described in Chang et al., 2004) were 
introduced into HeLa cells by transfection with the use of a Nucleofactor in-
strument (Amaxa Biosystems). 24 h later, cells were treated with the indi-
cated dose of MMC for 24 h. MTT assay was performed as described in 
the previous paragraph for cell viability assay. For immunoblotting, cells 
were lysed with RIPA buffer and separated by 8% SDS-PAGE followed by 
immunoblotting with FANCD2 antibody (Novus Biologicals).
Online supplemental material
Fig. S1 shows the mislocalization of PRDX3 in FA-G mutant ﬁ  broblasts.
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200607061/DC1.
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